Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study.

Some studies have also revealed that there is no marked difference in the response of luminal A and B tumors to aromatase inhibitors [ 31 ], which may suggest that although the risk for recurrence in the low PR expression group is relatively high, excessive drug use should be avoided during endocrine therapy to limit side effects, while the improvement in the prognosis of patients may not be significant.

also in 2,774 other papers